Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trial
- 30 November 1999
- journal article
- clinical trial
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 35 (12), 1659-1666
- https://doi.org/10.1016/s0959-8049(99)00141-0
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trialEuropean Journal Of Cancer, 1992
- “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)European Journal of Cancer and Clinical Oncology, 1991
- ADJUVANT THERAPY WITH TAMOXIFEN IN OPERABLE BREAST CANCER: 10 year results of the Naples (GUN) studyThe Lancet, 1988
- Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF+ tamoxifen in a single centreBreast Cancer Research and Treatment, 1988
- Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancerBreast Cancer Research and Treatment, 1985
- Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifenEuropean Journal of Cancer and Clinical Oncology, 1985
- BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUESThe Lancet, 1985
- Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancerBreast Cancer Research and Treatment, 1983
- 1-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer.Lack of association of disease-free survival with depression of ovarian functionCancer, 1979